PDF
File
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Scandinavian ChemoTech's first patient treated for pancreatic cancer at Ulis Hospital in Ukraine has been discharged from the hospital. The team has continued to treat a second pancreatic cancer patient this morning.
The team of specialists at Ulis Hospital in Ukraine is so far very pleased with the physical recovery of the first patient, whose tumour was deemed unresectable, where IQwave and TSE under open surgical procedure was chosen as an alternative. The procedure was done after due ethical and administrative approvals.
The team reported that the pathological response is very impressive. With this initial pathological response, the experts at Ulis are optimistic about a favourable outcome and survival rate and reported today day that the patient has been discharged from the hospital.
After the promising results achieved by the team, they performed the TSE treatment on yet another patient with pancreatic cancer today.
"We are very pleased to report that the first patient we treated with TSE for pancreatic cancer was in such good condition that we were able to discharge her from In-Patient care. The patient's promising response, which we could observe, gave us the confidence to perform yet another treatment. We intend to continue working in this direction."- says Professor Alexei Kovalev
"Safety first is a basic mantra of clinical practice. This has been proved by the oncology experts at ULIS hospital. The pathological response and a safe execution have enhanced the morale of the team to perform TSE on further unresectable pancreatic cancer cases. The ChemoTech Medical Affairs team is keeping a close watch observing the best practices of Pharmacovigilance and Materiovigilance." - says Dr. Suhail Mufti, Medical Advisor at Scandinavian ChemoTech.
" It is with great pleasure I take part of those initial result of treating pancreatic cancer patients at late stage that normally have a very poor prognosis. With more than 80% of all pancreatic cancer tumours being unresectable this new treatment procedure could be an important complement to current standard of care and give new hope to those patients." - says Rolf Ehrnström board director and also with experience as the CSO for Immunovia where focus is at early detection of pancreatic cancer